Driving Innovation Through Collaboration: The Future of mRNA Therapies
In this episode, we are joined by three experts—Christoph Hein (Fraunhofer IPK), Bern-hard Bobusch (FDX Fluid Dynamix), and Sönke Stocker (Lonza)—to explore how ad-vanced fluidics, encapsulation techniques, and a truly collaborative approach are paving the way for potential solid-tumor vaccines now in preclinical trials.
When you think about mRNA-based vaccines, have you ever considered the complex route these microscopic instructions must travel to deliver their life-changing code? This journey, essential for the therapy’s success, lies at the core of pharmaceutical research—where the challenge is to maximize stability and “bioavailability” so that each dose effec-tively reaches its cellular target.
By enclosing mRNA within lipid nanoparticles (LNPs) using sophisticated mixing tech-nologies, scientists can create the next generation of therapies—tailored to each patient’s needs. From prophylactic vaccines to personalized cancer treatments for solid tumors, these breakthroughs promise not only more effective but also safer medical solutions. In this episode, we spotlight FDmiX®, a groundbreaking mixer platform that enables the pre-cise production of LNPs, driving forward the possibility of new, life-saving vaccines in the fight against cancer.
Curious to Learn More?
Join us in this conversation hosted by Martina Ribar Hestericová, featuring Fraunhofer IPK’s Christoph Hein, FDX Fluid Dynamix’s Bernhard Bobusch, and Lonza’s Sönke Stocker, as they unveil how FDmiX® and mRNA encapsulation could revolutionize the development of solid-tumor vaccines and other cutting-edge therapies.
KEY TERMS:
Bispecific Antibodies: Advanced antibody formats designed to target two antigens simultaneously. These mole-cules enhance therapeutic precision by addressing multiple disease pathways in a single treatment, reducing the need for combination therapies.
CHO Cells (Chinese Hamster Ovary Cells): The workhorse of biologics manufacturing, CHO cells are engineered to produce large quantities of therapeutic antibodies with human-like glycan profiles, ensuring safety and efficacy at scale.
Process Intensification: A manufacturing innovation aimed at increasing productivity in bioreactors. By optimiz-ing processes, such as transitioning from fed-batch to continuous methods, process in-tensification allows for higher yields in less time.
Antibody Engineering: The application of recombinant DNA and structural biology tools to design antibodies with enhanced specificity, affinity, and functionality, enabling therapies to better ad-dress complex diseases like cancer and autoimmune disorders.
Synergistic Binding: A unique feature of multi-specific antibodies where binding to multiple antigens ampli-fies therapeutic effects beyond what is achievable with individual monoclonal antibod-ies or antibody cocktails. This approach increases efficacy and reduces treatment com-plexity.